SEC Form 4 · accession 0000899243-18-007302
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Director
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2,F3 | — | Mar 9, 2018 | D | 12,437 | D | — | — | Common Stock | 12,437 | 0 | D |
| Restricted Stock UnitsF4,F5,F3 | — | Mar 9, 2018 | D | 13,927 | D | — | — | Common Stock | 13,927 | 0 | D |
Explanation of responses
- F1Pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), the restricted stock units were cancelled in exchange for a cash payment of $124,370.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share.
- F2The restricted stock units were granted on April 3, 2017 and vest on the one-year anniversary of the grant date.
- F3The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
- F4Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share.
- F5The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.